Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Atrys Health's Enterprise Value is €445.5 Mil.
Atrys Health's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.6 Mil. Therefore, Atrys Health's EV-to-OCF for today is -285.78.
The historical rank and industry rank for Atrys Health's EV-to-OCF or its related term are showing as below:
XMAD:ATRY'
s EV-to-OCF Range Over the Past 10 Years
Min: -306.44 Med: 23.87 Max: 207.53
Current: -285.78
During the past 10 years, the highest EV-to-OCF of Atrys Health was 207.53. The lowest was -306.44. And the median was 23.87.
XMAD:ATRY's EV-to-OCF is ranked better than 98.29% of 1407
companies
in the Biotechnology industry
Industry Median: -3.45
vs XMAD:ATRY: -285.78
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Atrys Health's PE Ratio (TTM) for today is calculated as:
Atrys Health's share price for today is €2.645.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Atrys Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.322.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Atrys Health EV-to-OCF Related Terms
Atrys Health EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Atrys Health's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:ATRY vs VRTX, REGN, RVMD: EV-to-OCF Comparison
For the Biotechnology subindustry, Atrys Health's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atrys Health EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atrys Health's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Atrys Health's EV-to-OCF falls into.
Atrys Health's current Enterprise Value is €445.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Atrys Health's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atrys Health (XMAD:ATRY) has a EV-to-OCF of -285.78 as of Aug. 09, 2026. According to the industry distribution chart, Atrys Health ranks #24 out of 1407 companies in the Biotechnology industry, placing it in the top 1.7%.
Is Atrys Health's EV-to-OCF too high?
Atrys Health's current EV-to-OCF is -285.78. Based on the distribution chart, Atrys Health ranks #24 out of 1407 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Atrys Health has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Atrys Health ranks #24 out of 1407 companies for EV-to-OCF. This places Atrys Health in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Atrys Health's current EV-to-OCF is -285.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Fairly Valued. The stock's GF Value™ is €2.67, compared to a current price of €2.65 — trading 0.9% below its estimated fair value. The current EV-to-OCF is -285.78. Atrys Health's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current EV-to-OCF is -285.78 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Atrys Health (XMAD:ATRY) Overvalued in 2026?
Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued.
The current stock price of €2.65 is trading 0.9% below its estimated GF Value™ of €2.67.
GuruFocus considers Atrys Health to be Fairly Valued.
Key valuation signals for XMAD:ATRY:
EV-to-OCF: -285.78
GF Value™: €2.67 vs. price of €2.65 (0.9% below fair value)
No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
62GF Score
Get the complete analysis for XMAD:ATRY
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:ATRY has been successfully added to your 
